S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
New CBOE “special perk” helps traders target income every weekend (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
New CBOE “special perk” helps traders target income every weekend (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
New CBOE “special perk” helps traders target income every weekend (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
New CBOE “special perk” helps traders target income every weekend (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled

Tarsus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TARS)

$16.53
+0.06 (+0.36%)
(As of 11/30/2023 ET)
Compare
Today's Range
$16.03
$16.77
50-Day Range
$12.98
$18.86
52-Week Range
$11.33
$25.25
Volume
471,868 shs
Average Volume
309,315 shs
Market Capitalization
$547.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.20

Tarsus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
161.3% Upside
$43.20 Price Target
Short Interest
Bearish
13.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$272,472 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.86) to ($4.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

645th out of 948 stocks

Biological Products, Except Diagnostic Industry

108th out of 164 stocks


TARS stock logo

About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)

Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

TARS Stock Price History

TARS Stock News Headlines

Why Microsoft Just Placed A Huge Bet On Nuclear
Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.
Oppenheimer Keeps Their Buy Rating on Tarsus Pharmaceuticals (TARS)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Tarsus Pharmaceuticals Inc Ordinary Shares TARS
Analysts’ Top Healthcare Picks: Seelos Therapeutics (SEEL), Clene (CLNN)
Tarsus Pharmaceuticals (NASDAQ: TARS)
See More Headlines
Receive TARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/11/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TARS
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$43.20
High Stock Price Target
$54.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+163.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-62,090,000.00
Pretax Margin
-748.73%

Debt

Sales & Book Value

Annual Sales
$25.82 million
Book Value
$6.45 per share

Miscellaneous

Free Float
29,285,000
Market Cap
$542.51 million
Optionable
Not Optionable
Beta
0.79
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Bobak R. Azamian M.D.
    Co-Founder, President, CEO & Chairman
  • Dr. Bryan Wahl J.D. (Age 45)
    M.D., General Counsel & Corporate Secretary
    Comp: $619.09k
  • Dr. Elizabeth Yeu Lin M.D. (Age 45)
    Chief Medical Advisor & Director
    Comp: $286k
  • Dr. Jose Trevejo M.D. (Age 51)
    Ph.D., Chief Medical Officer
    Comp: $769.39k
  • Mr. Jeffrey S. Farrow (Age 61)
    CFO & Chief Strategy Officer
  • Dr. Seshadri Neervannan Ph.D. (Age 55)
    Chief Operating Officer
    Comp: $486.67k
  • Mr. David Nakasone
    Head of Investor Relations
  • Ms. Adrienne Kemp
    Senior Director of Corporate Communications
  • Mr. Matthew Rossen M.B.A. (Age 46)
    Vice President of Marketing
  • Mr. Scott Youmans
    Vice President of Sales














TARS Stock Analysis - Frequently Asked Questions

Should I buy or sell Tarsus Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TARS shares.
View TARS analyst ratings
or view top-rated stocks.

What is Tarsus Pharmaceuticals' stock price target for 2024?

4 brokerages have issued 1 year target prices for Tarsus Pharmaceuticals' stock. Their TARS share price targets range from $19.00 to $54.00. On average, they expect the company's share price to reach $43.20 in the next twelve months. This suggests a possible upside of 161.3% from the stock's current price.
View analysts price targets for TARS
or view top-rated stocks among Wall Street analysts.

How have TARS shares performed in 2023?

Tarsus Pharmaceuticals' stock was trading at $14.66 at the beginning of the year. Since then, TARS shares have increased by 12.8% and is now trading at $16.53.
View the best growth stocks for 2023 here
.

When is Tarsus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024.
View our TARS earnings forecast
.

How were Tarsus Pharmaceuticals' earnings last quarter?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.34. The firm earned $1.24 million during the quarter, compared to analysts' expectations of $1 million.

What ETF holds Tarsus Pharmaceuticals' stock ?

Invesco Raymond James SB-1 Equity ETF holds 39,637 shares of TARS stock, representing 0.71% of its portfolio.

When did Tarsus Pharmaceuticals IPO?

(TARS) raised $80 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 5,000,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.

Who are Tarsus Pharmaceuticals' major shareholders?

Tarsus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include RTW Investments LP (8.70%), Cowen AND Company LLC (5.51%), Deerfield Management Company L.P. Series C (2.28%), Artisan Partners Limited Partnership (1.22%), Allspring Global Investments Holdings LLC (0.75%) and Schonfeld Strategic Advisors LLC (0.74%). Insiders that own company stock include Aziz Mottiwala, Bobak R Azamian, Bobak R Azamian, Bryan Wahl, Dianne C Whitfield, Elizabeth Yeu Lin, Jose M Trevejo, Leonard M Greenstein, Mark J Holdbrook, Michael Ackermann, Rtw Investments, Lp, Seshadri Neervannan and Vivo Capital Ix, Llc.
View institutional ownership trends
.

How do I buy shares of Tarsus Pharmaceuticals?

Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TARS) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -